COMP <GO>
MBRX vs PTN // EV/EBITDA & P/E VALUATION
Moleculin Biotech Inc. (NASDAQ) VS. Palatin Technologies Inc. (NASDAQ) • 15-METRIC TALLY: MBRX 3
— PTN 0
■ METRIC PARITY
LAST: $8.72 (-0.29%) • MKT CAP: $9.2M
valuation
—
LAST: $4.93 (-3.33%) • MKT CAP: $8.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MBRX VS. PTN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MBRX | PTN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 1/9 | +2.00 | MBRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.6 | 25.3 | +19.31 | MBRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.2M | $8.8M | $376.0K | MBRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MBRX REV | PTN REV | MBRX GROSS % | PTN GROSS % | MBRX FCF | PTN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$22.7M | -$21.3M |
| FY 2024 | $0 | $4.5M | — | 97.8% | -$23.9M | -$31.5M |
| FY 2023 | $0 | $4.9M | — | — | -$23.6M | -$29.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MBRX // BETA —
PTN // BETA —